Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UNITED THERAPEUTICS CORPORATION

(UTHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Improve Slightly This Afternoon as Biotechs Struggle

03/03/2021 | 03:55pm EDT


ę MT Newswires 2021
All news about UNITED THERAPEUTICS CORPORATION
09/16INSIDER SELL : United Therapeutics
MT
09/15CAE : and BETA Technologies Detail Strategic Partnership For Pilot and Maintenance Trainin..
MT
09/10UNITED THERAPEUTICS : Releases its Annual Corporate Responsibility Report
PR
08/24UNITED THERAPEUTICS : to Present Tyvaso DPI™ BREEZE Clinical Data at the European Re..
PR
08/24United Therapeutics Corporation to Present Tyvaso DpiÖ Breeze Clinical Data At the Euro..
CI
08/20UNITED THERAPEUTICS : 2020 Annual Report
PU
08/13LIQUIDIA : U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes ..
AQ
08/12LIQUIDIA : Says US PTAB Initiates Review of United Therapeutics' Tyvaso Patent
MT
08/11LIQUIDIA : Reports Second Quarter 2021 Financial Results and Provides Corporate Update
AQ
08/04UPDATE : United Therapeutics Shares Jump 14% After Q2 Gains Exceed Estimates
MT
More news
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 671 M - -
Net income 2021 524 M - -
Net cash 2021 509 M - -
P/E ratio 2021 17,5x
Yield 2021 -
Capitalization 8 911 M 8 911 M -
EV / Sales 2021 5,03x
EV / Sales 2022 4,16x
Nbr of Employees 950
Free-Float 60,7%
Chart UNITED THERAPEUTICS CORPORATION
Duration : Period :
United Therapeutics Corporation Technical Analysis Chart | UTHR | US91307C1027 | MarketScreener
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 198,51 $
Average target price 231,89 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Martine A. Rothblatt Chairman & Chief Executive Officer
Michael Ian Benkowitz President & Chief Operating Officer
James Christopher Edgemond Chief Financial Officer & Treasurer
Raymond C. Kurzweil Independent Director
Louis Wade Sullivan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNITED THERAPEUTICS CORPORATION30.78%8 911
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939